ChemoCentryx completes Series C financing

ChemoCentryx announced it completed $17.7 million in Series C financing.
| 1 min read
Register for free to listen to this article
Listen with Speechify
0:00
1:00
MOUNTAIN VIEW, Calif.—On the same day that it announced the signing of a major research col­laboration with GSK (see story), ChemoCentryx announced it completed $17.7 million in Series C financing. When added to the $63.5 million in upfront fund­ing it will receive from GSK and other financing vehicles, ChemoCentryx has achieved about $90 million in new mon­ies in 2006.
 
"Historically, we have suc­cessfully pursued a mix of venture capital financing and non-dilutive funding," said Dr. Thomas J. Schall, company president and CEO, in a pre­pared statement. "The combi­nation of our Series C financ­ing and the upfront payments received as part of our strategic alliance with GSK reinforces this long-term strategy. We are now extremely well-positioned to avail ourselves of market opportunities of our choosing, as we continue to build value in ChemoCentryx and our pipe­line of chemokine-based medicines."
 
The Series C investors include Jennison Associates, HBM BioVentures, Orbimed Advisors, Techne Corporation, Alta Partners and GIMV.

About the Author

Related Topics

Published In

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Image Alt Text	A laboratorian wearing blue gloves places a PCR sample into a real-time PCR thermocycler, the model shown is blue and white with a large digital screen.
From primer design to sample preparation, explore comprehensive strategies to optimize PCR throughput and reproducibility.
Tackling mycoplasma contamination in biotherapeutic production
DNA-based testing is emerging as a sensitive way to uncover and control a hidden threat in biomanufacturing.
Surface rendering of two interacting proteins (green and peach) bound together by a small molecule ligand at their interface, illustrating a protein-ligand binding event.
Learn how molecular dynamics, AI-aided design, and structural insights combine to reshape how therapeutic proteins are created, validated, and optimized.
Drug Discovery News June 2025 Issue
Latest IssueVolume 21 • Issue 2 • June 2025

June 2025

June 2025 Issue

Explore this issue